back to Australia directory
australia clinical guidance

Atrial fibrillation

A detailed Australian summary of atrial fibrillation, with source-attributed priorities, a practical workflow, safety escalation and state or territory implementation boundaries.

JurisdictionAustralia
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceHealthcare professionals practising in Australia
This is an iatroX educational summary of named Australia sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Apply current TGA product information, PBS restrictions, state or territory law, local referral criteria, formulary and antimicrobial policy. A national recommendation does not create uniform service access.

Scope

Confirm atrial fibrillation on an ECG and characterize symptom burden, pattern, ventricular rate, precipitating illness and structural heart disease. Assess stroke and bleeding risk separately; bleeding risk should trigger correction and monitoring of modifiable factors rather than automatic withholding of anticoagulation. This summary is limited to the population, decisions and escalation boundaries stated in the named source.
sources for this section:NHFA/CSANZ AF

The Bottom Line

  • Confirm atrial fibrillation on an ECG and characterize symptom burden, pattern, ventricular rate, precipitating illness and structural heart disease.
  • Assess stroke and bleeding risk separately; bleeding risk should trigger correction and monitoring of modifiable factors rather than automatic withholding of anticoagulation.
  • Calculate creatinine clearance with the method required by the anticoagulant product information rather than relying only on laboratory eGFR.
  • Discuss anticoagulation using absolute benefit, bleeding risk, kidney function, interactions, adherence and patient preference, then review it longitudinally.
sources for this section:NHFA/CSANZ AF

Practical clinical workflow

1

Topic-specific assessment action

Confirm atrial fibrillation on an ECG and characterize symptom burden, pattern, ventricular rate, precipitating illness and structural heart disease.
2

Topic-specific diagnostic action

Discuss anticoagulation using absolute benefit, bleeding risk, kidney function, interactions, adherence and patient preference, then review it longitudinally.
3

Topic-specific management action

Choose rate or rhythm control according to haemodynamic stability, symptoms, duration, heart failure, comorbidity and specialist input rather than age alone.
4

Topic-specific follow-through

Screen for obstructive sleep apnoea, obesity, hypertension, alcohol and inactivity because risk-factor management supports rhythm outcomes.
sources for this section:NHFA/CSANZ AF

Safety boundaries and escalation

  • Haemodynamic compromise, ongoing ischaemic chest pain, pulmonary oedema or pre-excited rapid atrial fibrillation requires immediate emergency management.
  • For cardioversion, confirm onset and anticoagulation requirements under the Australian pathway and do not infer safety from symptom duration alone.
sources for this section:NHFA/CSANZ AF

Implementation

The named source is national or binational guidance used in Australia, but referral access, public-health directions, formularies and funded services can still differ by state, territory and health service. Check current TGA product information for medicines. Offer culturally safe care and use the NACCHO鈥揜ACGP National Guide where Aboriginal and Torres Strait Islander preventive or chronic-care recommendations differ.
sources for this section:NHFA/CSANZ AF

Clinical use boundary

This independently written summary is not an official guideline. Check the linked source version, current TGA-approved product information where medicines are involved, and the applicable state, territory and local pathway at the point of care.

sources for this section:NHFA/CSANZ AF

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. National Heart Foundation of Australia and Cardiac Society of Australia and New ZealandAustralian Clinical Guidelines for the Diagnosis and Management of Atrial Fibrillation 2018DOI 10.1016/j.hlc.2018.06.1043 路 2018 guideline; current Heart Foundation source page checked 2026-08-20 路 accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the Australia question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.